Welcome to our dedicated page for INTL STEM CELL news (Ticker: ISCO), a resource for investors and traders seeking the latest updates and insights on INTL STEM CELL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INTL STEM CELL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INTL STEM CELL's position in the market.
International Stem Cell Corporation (ISCO) has reported financial results for Q1 2022, showcasing significant growth. Consolidated revenue reached $2.02 million, marking a 22% increase from $1.66 million in Q1 2021. The company reported a combined operating income of $648,000, which is up 164% from $245,000 year-over-year. Notably, ISCO's net loss shrank to $9,000, a substantial improvement from a net loss of $599,000 in the same quarter of the previous year. CEO Andrey Semechkin highlighted the positive trajectory of business units and the progress of their Phase 1 clinical trial.
International Stem Cell Corporation (ISCO) announced its 2021 financial results and provided updates on its phase 1 clinical trial for ISC-hpNSC® in treating Parkinson's disease. The company reported a slight revenue increase to $7.18 million, with a notable 127% rise in operating income to $1.35 million. The net loss significantly decreased to $899,000. In clinical outcomes, patients in the trial demonstrated a 47% reduction in % OFF-Time at 12 months and a 43% improvement in quality of life, validating the treatment's safety and efficacy over 48 months.
International Stem Cell Corporation (OTCQB:ISCO) announced the successful completion of its Phase 1 clinical trial for ISC-hpNSC® in treating Parkinson's disease. The trial evaluated the safety and tolerability of various doses over 24 months, revealing no serious adverse effects. Patients showed significant improvements, including a 55% reduction in % OFF-Time and a 45% improvement in quality of life. The company is optimistic about further research to determine the most effective dosage for enhanced efficacy.
FAQ
What is the current stock price of INTL STEM CELL (ISCO)?
What is the market cap of INTL STEM CELL (ISCO)?
